US9511030B2 - Controlled release particles - Google Patents

Controlled release particles Download PDF

Info

Publication number
US9511030B2
US9511030B2 US14/003,271 US201214003271A US9511030B2 US 9511030 B2 US9511030 B2 US 9511030B2 US 201214003271 A US201214003271 A US 201214003271A US 9511030 B2 US9511030 B2 US 9511030B2
Authority
US
United States
Prior art keywords
polymer
suspension
controlled release
compound
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US14/003,271
Other languages
English (en)
Other versions
US20130337073A1 (en
Inventor
Junji Oshima
Takayuki Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Gas Chemicals Co Ltd
Original Assignee
Osaka Gas Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Gas Chemicals Co Ltd filed Critical Osaka Gas Chemicals Co Ltd
Assigned to JAPAN ENVIROCHEMICALS, LTD. reassignment JAPAN ENVIROCHEMICALS, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OSHIMA, JUNJI, SUGIYAMA, TAKAYUKI
Publication of US20130337073A1 publication Critical patent/US20130337073A1/en
Assigned to OSAKA GAS CHEMICALS CO., LTD. reassignment OSAKA GAS CHEMICALS CO., LTD. MERGER AND CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: JAPAN ENVIROCHEMICALS, LTD., OSAKA GAS CHEMICALS CO., LTD.
Application granted granted Critical
Publication of US9511030B2 publication Critical patent/US9511030B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
    • A01N25/28—Microcapsules or nanocapsules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647—Triazoles; Hydrogenated triazoles
    • A01N43/653—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/10—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
    • A01N47/12—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof containing a —O—CO—N< group, or a thio analogue thereof, neither directly attached to a ring nor the nitrogen atom being a member of a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
    • A01N47/38—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N< containing the group >N—CO—N< where at least one nitrogen atom is part of a heterocyclic ring; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N53/00—Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur

Definitions

  • the present invention relates to controlled release particles, in particular, to controlled release particles that allow controlled-release of an antibiotic compound.
  • antibiotic compounds such as a sterilizer, an antiseptic, and a fungicide allows controlled-release of the antibiotic compound to ensure lasting effects.
  • a microbial growth inhibitor-containing microcapsule for example, see Patent Document 1 below: the microbial growth inhibitor-containing microcapsule is obtained by blending and dispersing an oil phase including a microbial growth inhibitor and a polyisocyanate component, and an aqueous phase including an active hydrogen group-containing component, and allowing interfacial polymerization.
  • Patent Document 1 there are disadvantages in the above-described Patent Document 1 in that the microbial growth inhibitor-containing microcapsule described in Patent Document 1 has insufficient controlled release properties.
  • An object of the present invention is to provide controlled release particles excellent in controlled release properties.
  • the present inventors made an energetic study on the controlled release particles of the above object, and found out that controlled release particles have excellent controlled release properties by including a core containing an antibiotic compound present in the first polymer and a shell composed of a second polymer, and as a result of further advancing the study, accomplished the present invention.
  • a controlled release particle of the present invention includes,
  • a core formed by suspension polymerization of a core ingredient component containing an antibiotic compound and a first polymerizable vinyl monomer, and containing a first polymer of the first polymerizable vinyl monomer and the antibiotic compound present in the first polymer;
  • a controlled release particle of the present invention includes a core containing a first polymer obtained from a first polymerizable vinyl monomer, and an antibiotic compound present in a matrix composed of the first polymer; and a shell composed of a second polymer and is formed so as to cover the core. Therefore, by suppressing the releasing speed of the antibiotic compound, the controlled release particle of the present invention has excellent controlled release properties, and exhibits excellent lasting effects.
  • FIG. 1 shows an image-processed TEM photograph of controlled release particles of Example 4.
  • the controlled release particle ( 1 ) of the present invention includes a core ( 2 ), and a shell ( 3 ) that covers the core ( 2 ).
  • the core ( 2 ) is generally spherical, and contains a first polymer and an antibiotic compound.
  • the shell ( 3 ) is formed into a membrane that covers the surface of the core ( 2 ), and contains a second polymer.
  • the shell ( 3 ) is formed along the periphery of the core ( 2 ), and has a comparatively smooth surface.
  • the core ( 2 ) is formed by suspension polymerization of a core ingredient component containing the antibiotic compound and a first polymerizable vinyl monomer
  • the shell ( 3 ) is formed by suspension polymerization of a second polymerizable vinyl monomer.
  • the antibiotic compound has, for example, at least two functional moieties that are capable of interacting with the polymer of the first polymerizable vinyl monomer.
  • Such functional moieties include polar functional groups such as a carbonyl group, a nitro group, an amino group, a cyano group, a phosphate group, a carboxyl group, and an ether group; polar bonds containing a polar group such as a carboxylate bond, a phosphate bond, a urea bond, and a carbon-halogen bond; and conjugated cyclic portions such as a benzene ring, and further a conjugated heterocyclic ring such as a triazine ring, an imidazole ring, and an isothiazoline ring.
  • polar functional groups such as a carbonyl group, a nitro group, an amino group, a cyano group, a phosphate group, a carboxyl group, and an ether group
  • polar bonds containing a polar group such as a carboxylate bond, a phosphate bond, a urea bond, and a carbon-halogen bond
  • the antibiotic compound has a molecular weight of, for example, 200 to 600, preferably 200 to 500.
  • the antibiotic compound When the antibiotic compound has a molecular weight exceeding the above-described range, miscibility of the antibiotic compound with the first polymer may be reduced. On the other hand, when the antibiotic compound has a molecular weight below the above-described range, there is a case where the antibiotic compound remains in the aqueous phase during suspension polymerization, and after the suspension polymerization, the antibiotic compound separates out, solidifying the first suspension liquid.
  • the antibiotic compound has a melting point of, for example, 100° C. or less, preferably 90° C. or less, and more preferably 80° C. or less.
  • a melting point exceeds the above-described range, there may be a case where the antibiotic compound is not easily encapsulated in the core and separates outside the core, and even if the antibiotic compound is encapsulated in the core, controlled-release of the antibiotic compound to the outside the core may not be allowed.
  • the antibiotic compound is selected from a sterilizer, an antibacterial agent, an antiseptic, an antialgae, a fungicide, an insecticide, a herbicide, an attractant, a repellent, a rodenticide, etc. having antibiotic activities such as, for example, sterilizing, antibacterial, antiseptic, antialgae, antifungal, and insecticidal activity.
  • Examples of these compounds having antibiotic activity include sterilizing antiseptic antialgae fungicides such as an iodine compound, a triazole compound, a carbamoyl imidazole compound, a dithiol compound, an isothiazoline compound, a nitro alcohol compound, and p-hydroxybenzoate ester; and termite control agents (termite killers) such as a pyrethroid compound, a neonicotinoid compound, an organic chlorine compound, an organic phosphorus compound, a carbamate compound, an alkoxyamine compound, and an oxadiazon compound.
  • antiseptic antialgae fungicides such as an iodine compound, a triazole compound, a carbamoyl imidazole compound, a dithiol compound, an isothiazoline compound, a nitro alcohol compound, and p-hydroxybenzoate ester
  • termite control agents such as a pyrethroid compound, a neonico
  • iodine compounds include 3-iodo-2-propynylbutylcarbamate (IPBC), 1-[[(3-iodo-2-propynyl)oxy]methoxy]-4-methoxybenzene, and 3-bromo-2,3-diiodo-2-propenyl ethyl carbonate.
  • IPBC 3-iodo-2-propynylbutylcarbamate
  • 1-[[(3-iodo-2-propynyl)oxy]methoxy]-4-methoxybenzene 2-bromo-2,3-diiodo-2-propenyl ethyl carbonate.
  • triazole compounds examples include 1-[2-(2,4-dichlorophenyl)-4-n-propyl-1,3-dioxolane-2-ylmethyl]-1H-1,2,4-triazole (propiconazole), and bis(4-fluorophenyl)methyl (1H-1,2,4-triazole-1-ylmethylsliane) (also called: flusilazole, 1-[[bis(4-fluorophenyl) methylsilyl]methyl]-1H-1,2,4-triazole).
  • carbamoyl imidazole compounds examples include N-propyl-N-[2-(2,4,6-trichloro-phenoxy)ethyl]imidazole-1-carboxamide (prochloraz).
  • dithiol compounds examples include 4,5-dichloro-1,2-dithiol-3-one.
  • isothiazoline compounds include 2-n-octyl-4-isothiazoline-3-one (OIT), 5,6-dichloro-2-n-octyl-4-isothiazoline-3-one (DCOIT), and 5-chloro-2-methyl-4-isothiazoline-3-one (Cl-MIT).
  • nitro alcohol compounds examples include 2,2-dibromo-2-nitro-1-ethanol (DBNE).
  • p-hydroxybenzoate esters examples include butyl p-hydroxybenzoate and propyl p-hydroxybenzoate.
  • neonicotinoid compounds include (E)-N 1 -[(6-chloro-3-pyridyl)methyl]-N 2 -cyano-N 1 -methylacetamidine (acetamiprid).
  • organic chlorine compounds examples include Kelthane.
  • organic phosphorus compounds examples include phoxim, pyridaphenthion, fenitrothion, tetrachlorvinphos, dichlofenthion, and propetamphos.
  • carbamate compounds examples include fenobucarb and propoxur.
  • alkoxyamine compound examples include 3-lauryloxypropylamine.
  • oxadiazon compounds examples include indoxacarb.
  • insecticides examples include pyriproxyfen.
  • herbicides examples include pyraclonil, pendimethalin, and indanofan.
  • repellents examples include Deet.
  • the antibiotic compound is substantially hydrophobic, and, to be specific, has a quite low water solubility at room temperature (20 to 30° C., to be more specific, 25° C.), to more be specific, for example, a solubility at room temperature of on a mass basis, 1 part by mass/100 parts by mass of water (10000 ppm) or less, preferably 0.5 parts by mass/100 parts by mass of water (5000 ppm) or less, and more preferably 0.1 parts by mass/100 parts by mass of water (1000 ppm) or less; and on a volume basis, for example, 1 g/100 mL of water or less, preferably 0.5 g/100 mL of water or less, and more preferably 0.1 g/100 mL of water or less.
  • the antibiotic compound When the antibiotic compound has a water solubility exceeding the above-described range, at the time of suspension polymerization of a core ingredient component containing the first polymerizable vinyl monomer, the antibiotic compound easily leaks out to the outside (that is, aqueous phase) of the core, and after the polymerization, the antibiotic compound dissolved in the aqueous phase separates out, and therefore formation of the core containing the antibiotic compound may become difficult.
  • antibiotic compounds can be used alone or in combination of two or more.
  • the above-described antibiotic compound may contain, for example, in the production processes, impurities having a melting point of outside the above-described range at an appropriate proportion.
  • impurities having a melting point of outside the above-described range at an appropriate proportion.
  • a mixture of isomer I (melting point: 57° C.), isomer II (melting point: 74° C.), and isomer III (melting point: 66° C.) of cyfluthrin contains, for example, an impurity of isomer IV (melting point 102° C.).
  • the first polymerizable vinyl monomer is, for example, a monomer having at least one polymerizable carbon-carbon double bond in its molecule.
  • examples of the first polymerizable vinyl monomer include a (meth)acrylate monomer, a (meth)acrylic acid monomer, an aromatic vinyl monomer, a vinyl ester monomer, a maleate monomer, a vinyl halide monomer, and a nitrogen-containing vinyl monomer.
  • Examples of (meth)acrylate monomers include methacrylates and/acrylates, to be specific, (meth) acrylic acid alkyl ester having an alkyl moiety of a straight chain or branched aliphatic group with 1 to 20 carbon atoms including methyl (meth)acrylate, ethyl (meth)acrylate, propyl (meth)acrylate, isopropyl (meth)acrylate, butyl (meth)acrylate, isobutyl (meth)acrylate, tert-butyl (meth)acrylate, hexyl (meth)acrylate, octyl (meth)acrylate, nonyl (meth)acrylate, isononyl (meth)acrylate, decyl (meth)acrylate, dodecyl (meth)acrylate, hexadecyl (meth)acrylate, and octadecyl (meth)acrylate; and (meth) acrylic acid
  • (meth) acrylic acid alkyl ester having an alkyl moiety of a straight chain or branched aliphatic group with 1 to 6 carbon atoms (preferably, having 1 to 3 carbon atoms or having 4 to 6 carbon atoms) is used.
  • Examples of (meth) acrylic acid ester monomers also include hydroxyl group-containing (meth) acrylic acid alkyl ester in which the hydrogen atoms in the alkyl moiety are replaced with hydroxyl groups in the above-described monomer, and which has a hydroxyalkyl moiety with 2 to 10 carbon atoms, to be specific, 2-hydroxyethyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate, and 6-hydroxyhexyl (meth)acrylate.
  • hydroxyl group-containing (meth) acrylic acid alkyl ester having a hydroxyalkyl moiety having an acrylic moiety with 2 to 6 carbon atoms (preferably, with 2 to 3 carbon atoms) is used.
  • Examples of (meth) acrylic acid monomers include methacrylic acid and acrylic acid.
  • aromatic vinyl monomers examples include styrene, 4-chlorostyrene, p-methyl styrene, o-methyl styrene, and ⁇ -methyl styrene.
  • vinyl ester monomers examples include vinyl acetate and vinyl propionate.
  • maleate monomers examples include dimethyl maleate, diethyl maleate, and dibutyl maleate.
  • vinyl halide monomers examples include vinyl chloride and vinyl fluoride.
  • vinyl halide monomer also include vinylidene halide monomers, to be specific, vinylidene chloride and vinylidene fluoride.
  • nitrogen-containing vinyl monomers examples include (meth)acrylonitrile, N-phenylmaleimide, and vinylpyridine.
  • the first polymerizable vinyl monomer is substantially hydrophobic, and to be specific, has a significantly low water solubility at room temperature, to be more specific, a solubility at room temperature of, for example, 10 parts by mass/100 parts by mass of water or less, preferably 8 parts by mass/100 parts by mass of water or less.
  • an antibiotic compound-miscible monomer (hereinafter sometimes simply referred to as a miscible monomer) that is highly miscible with the above-described antibiotic compound and is capable of dissolving (being miscible with) the antibiotic compound is selected.
  • miscible monomers can be used alone or in combination of two or more.
  • miscible monomer preferably, a (meth)acrylate monomer and a (meth)acrylic acid monomer are used in combination.
  • MMA methyl methacrylate
  • MA methacrylic acid
  • IBMA isobutyl methacrylate
  • MA methacrylic acid
  • the mixing ratio of the (meth)acrylic acid monomer relative to 100 parts by mass of the miscible monomer is, for example, below 30 parts by mass, preferably 20 parts by mass or less, and, for example, 1 part by mass or more, preferably 3 parts by mass or more.
  • a combination of the antibiotic compound and the miscible monomer is selected so that, preferably, the first polymer, i.e., a polymer of the first polymerizable vinyl monomer, and the antibiotic compound are miscible at a polymerization temperature (heating temperature) to be described later.
  • the first polymer i.e., a polymer of the first polymerizable vinyl monomer
  • the antibiotic compound are miscible at a polymerization temperature (heating temperature) to be described later.
  • the first polymerizable vinyl monomer can contain a crosslinkable monomer as the miscible monomer.
  • the crosslinkable monomer is blended as necessary to adjust controlled release properties of the controlled release particles, and examples of the crosslinkable monomer include mono or polyethylene glycol di(meth)acrylate such as ethylene glycol di(meth)acrylate and diethylene glycol di(meth)acrylate; alkane diol di(meth)acrylate such as 1,3-propanediol di(meth)acrylate, 1,4-butanediol di(meth)acrylate, and 1,5-pentanediol di(meth)acrylate; alkane polyol poly (meth)acrylate such as trimethylolpropane tri(meth)acrylate and pentaerythritol tetra(meth)acrylate; allyl monomers such as allyl (meth) methacrylate, and triallyl (iso)cyanurate; and divinyl monomers such as divinylbenzene.
  • mono or polyethylene glycol di(meth)acrylate is used
  • the crosslinkable monomer a monomer having a molecule structure that is similar to that of the miscible monomer excluding the crosslinkable monomer is selected to ensure miscibility of the antibiotic compound and the monomer mixture (first polymerizable vinyl monomer) including the crosslinkable monomer; to be specific, when the miscible monomer excluding the crosslinkable monomer contains a (meth) acrylic acid ester monomer, preferably, mono or polyethylene glycol di(meth)acrylate is selected as the crosslinkable monomer.
  • a monomer having a molecule structure that is similar to that of the miscible monomer excluding the crosslinkable monomer is selected to ensure miscibility of the antibiotic compound and the monomer mixture (first polymerizable vinyl monomer) including the crosslinkable monomer; to be specific, when the miscible monomer excluding the crosslinkable monomer contains a (meth) acrylic acid ester monomer, preferably, mono or polyethylene glycol di(meth)acrylate is selected as the crosslinkable monomer.
  • the mixing ratio of the crosslinkable monomer relative to 100 parts by mass of the miscible monomer excluding the crosslinkable monomer is, for example, 1 to 100 parts by mass, preferably 5 to 90 parts by mass, and more preferably 10 to 80 parts by mass.
  • indexes “compound”, “first polymer”, and “second polymer” in each term ⁇ represent the antibiotic compound, the first polymer, and the second polymer, respectively.
  • the polar term ⁇ p and the hydrogen bonding term ⁇ h of the solubility parameter ⁇ defined by Hansen and calculated by van Krevelen and Hoftyzer method depend on the types and the number of the atomic group (including chemical bond or substituent), to be specific, are represented by following formulas (1) and (2), respectively.
  • F p of the substituent >Si ⁇ , ⁇ N—, and ⁇ C— is also calculated in the above-described manner.
  • the above-described calculation process is recorded in a computer as a program, and optimized.
  • PMMA polymethyl methacrylate
  • a polar term ⁇ p,PMMA and a hydrogen bonding term ⁇ h,PMMMA of the solubility parameter ⁇ of polymethyl methacrylate is calculated.
  • Polymethyl methacrylate is represented by formula (3) below.
  • polar term ⁇ p,monomer unit of the monomer unit is calculated, as shown in formula (4) below, to be 5.98[(J/cm 3 ) 1/2 ].
  • the polar term ⁇ p,monomer unit of the above-described monomer unit is rendered the polar term ⁇ p,PMMA of polymethyl methacrylate, having a repeating structure of the monomer unit.
  • the polar term ⁇ p,monomer unit of monomer units By multiplying the polar term ⁇ p,monomer unit of monomer units by the mass ratio of the monomer, and by adding these, the polar term ⁇ p,copolymer of the solubility parameter ⁇ of the copolymer is calculated. Also, by multiplying the hydrogen bonding term ⁇ h,monomer unit of the monomer units by the mass ratio of the monomer, and adding these, the hydrogen bonding term ⁇ h,copolymer of the solubility parameter ⁇ of the copolymer is calculated.
  • a polymethyl methacrylate-polymethacrylic acid-ethylene glycol dimethacrylate copolymer i.e., a copolymer of a monomer containing methyl methacrylate, methacrylic acid, and ethylene glycol dimethacrylate in a mass ratio of 75:12.5:12.5 (corresponds to the mass ratio of Example 1 to be described later), is used, and its polar term ⁇ p,PMMA-PMA-EGDMA and the hydrogen bonding term ⁇ h,PMMA-PMA-EGDMA of the solubility parameter ⁇ are calculated.
  • ⁇ p,MMA unit of the monomer unit of methyl methacrylate is, as calculated above, 5.98[(J/cm 3 ) 1/2 ].
  • ⁇ p,MA unit of the monomer unit of methacrylic acid calculated as described above is, 7.36[(J/cm 3 ) 1/2 ].
  • ⁇ p, EDGMA of the monomer unit of ethylene glycol dimethacrylate is calculated in the same manner as above, and determined to be 5.37[(J/cm 3 ) 1/2 ].
  • ⁇ p,PMMA-PMA-EGDMA The polar term ⁇ p,PMMA-PMA-EGDMA of the copolymer is calculated as shown in formula (6) below.
  • the hydrogen bonding term ⁇ h,MMA Unit of the monomer unit of methyl methacrylate is 9.25[(J/cm 3 ) 1/2 ].
  • the hydrogen bonding term ⁇ h,MA unit of the monomer unit of methacrylic acid is 9.25[(J/cm 3 ) 1/2 ].
  • the hydrogen bonding term ⁇ h,EGDMA of the monomer unit of ethylene glycol dimethacrylate is 10.42[(J/cm 3 ) 1/2 ].
  • the hydrogen bonding term ⁇ h,PMMA-PMA-EGDMA of the copolymer is calculated as shown in formula (7) below.
  • the polar term ⁇ p,first polymer of the solubility parameter ⁇ of the first polymer is preferably 4.25 to 6.5[(J/cm 3 ) 1/2 ], and the hydrogen bonding term ⁇ h,first polymer of the solubility parameter ⁇ of the first polymer is preferably 8.25 to 10[(J/cm 3 ) 1/2 ].
  • first polymer becomes excessively hydrophobic, and sufficient miscibility with the antibiotic compound may not be obtained, and even if miscibility was obtained, the antibiotic compound leaks to the outside of the core during the suspension polymerization, making synthesis of controlled release particles in which the antibiotic compound is sufficiently encapsulated difficult.
  • first polymer of the first polymer exceeds the above-described range, there may be a case where hydrophilicity of the first polymer becomes excessively high and sufficient miscibility with the antibiotic compound cannot be obtained, and even if miscibility could be obtained, interfacial free energy with the aqueous phase in the suspension polymerization is lowered, and antibiotic compound leaks to the outside of the core during the suspension polymerization, making synthesis of the core in which the antibiotic compound is sufficiently encapsulated difficult.
  • the polar term ⁇ p,compound and the hydrogen bonding term ⁇ h,compound of the solubility ⁇ of the antibiotic compound are also calculated in the same manner as that of the above-described monomer unit.
  • Table 1 shows the results of the calculated polar term ⁇ p, compound and hydrogen bonding term ⁇ h,compound of antibiotic compounds, i.e., IPBC, OIT, cyfluthrin, propiconazole, prochloraz, and flusilazole.
  • the polar term ⁇ p, compound of solubility parameter ⁇ of the antibiotic compound is preferably 3 to 7[(J/cm 3 ) 1/2 ] and the hydrogen bonding term ⁇ h, compound is preferably 5.8 to 9.5 [(J/cm 3 ) 1/2 ].
  • ⁇ p1 and ⁇ h1 are within the above-described range, excellent miscibility of the antibiotic compound and the first polymer can be ensured, ensuring excellent controlled release properties.
  • the antibiotic compound is defined as being miscible with the first polymer without leaking from the core during suspension polymerization.
  • the ratio of the antibiotic compound relative to the first polymerizable vinyl monomer is, on a mass basis (that is, parts by mass of the antibiotic compound/parts by mass of the first polymerizable vinyl monomer), for example, 10/90 to 90/10 (that is, 0.11 to 9.0), preferably 10/90 to 70/30 (that is, 0.11 to 2.33).
  • the second polymerizable vinyl monomer has affinity (that is, hydrophilicity) with water that is higher than that of the first polymerizable vinyl monomer (to be specific, miscible monomer), and to be specific, examples thereof include those monomers that are the same types as those of the above-described first polymerizable vinyl monomers, and that have high affinity with water.
  • Examples of the second polymerizable vinyl monomer that may be used is, preferably, (meth)acrylic acid ester monomers, more preferably, hydroxyl group-containing (meth)acrylic acid alkyl ester and (meth)acrylic acid alkyl ester.
  • hydroxyl group-containing (meth)acrylic acid alkyl ester (to be specific, hydroxyl group-containing (meth)acrylic acid alkyl ester having a hydroxyalkyl moiety with 2 to 3 carbon atoms) is used singly, (meth)acrylic acid alkyl ester (to be specific, (meth)acrylic acid alkyl ester having an alkyl moiety with 1 to 3 carbon atoms) is used singly, or they are used in combination.
  • the hydroxyl group-containing (meth)acrylic acid alkyl ester having a hydroxyalkyl moiety with 2 to 3 carbon atoms is used singly as the second polymerizable vinyl monomer, for example, a combination of (meth)acrylic acid alkyl ester having 4 to 6 carbon atoms and (meth)acrylic acid monomer, preferably, a combination of (meth)acrylic acid alkyl ester having 4 carbon atoms and methacrylic acid is used as the first polymerizable vinyl monomer.
  • (meth)acrylic acid alkyl ester having an alkyl moiety with 1 to 3 carbon atoms is used singly as the second polymerizable vinyl monomer, for example, a combination of (meth)acrylic acid alkyl ester having 4 to 6 carbon atoms and a (meth)acrylic acid monomer, preferably, a combination of (meth)acrylic acid alkyl ester having 4 carbon atoms and methacrylic acid is selected as the first polymerizable vinyl monomer.
  • a combination of hydroxyl group-containing (meth)acrylic acid alkyl ester having a hydroxyalkyl moiety with 2 to 3 carbon atoms and (meth)acrylic acid alkyl ester having an alkyl moiety with 1 to 3 carbon atoms are used in combination as the second polymerizable vinyl monomer, for example, a combination of (meth)acrylic acid alkyl ester having 4 to 6 carbon atoms and (meth) an acrylic acid ester monomer, preferably, a combination of (meth)acrylic acid alkyl ester having 4 carbon atoms and methacrylic acid is selected as the first polymerizable vinyl monomer.
  • the polar term ⁇ p,second polymer of the second polymer i.e., the polymer of the above-described second polymerizable vinyl monomer, is, for example, 5.0 to 9.0[(J/cm 3 ) 1/2 ], preferably, 6.5 to 8.0[(J/cm 3 ) 1/2 ], and the hydrogen bonding term ⁇ h,second polymer of the solubility parameter ⁇ of the second polymer is, for example, 8.0 to 20.0[(J/cm 3 ) 1/2 ], preferably, 12.0 to 18.0[(J/cm 3 ) 1/2 ].
  • the second polymer and/or the hydrogen bonding term ⁇ h,second polymer of the second polymer exceed the above-described range, the second polymer becomes excessively hydrophilic, and the second polymer forming the shell dissolves in water or absorbs water to swell, which makes it difficult to maintain the shape of the shell.
  • the polar term ⁇ p,second polymer and/or the hydrogen bonding term ⁇ h,second polymer of the second polymer are below the above-described range, there may be a case where the second polymer is insufficiently hydrophilic, the shell cannot achieve the barrier layer functions to be described later, and is miscible with the antibiotic compound to cause the antibiotic compound to leak to the outside of the shell.
  • ⁇ p2 and/or ⁇ h2 are below the above-described lower limit value, there may be a case where affinity with water of the second polymer cannot be made higher than that of the first polymer, and thus functions of the barrier layer to be described later cannot be achieved, and as a result, and the second polymer is miscible with the antibiotic compound to cause the antibiotic compound to leak to the outside of the shell.
  • ⁇ p2 and/or ⁇ h2 exceed the above-described upper limit value, there may be a case where affinity with water of the second polymer becomes excessive (excessively hydrophilic), and the second polymer dissolves in water or absorbs water to swell, which makes it difficult to maintain the shape of the shell.
  • affinity with water (hydrophilic/hydrophilicity) of the second polymer becomes higher than the first polymer.
  • the second polymerizable vinyl monomer is defined as having higher affinity (hydrophilicity) with water than that of the first polymerizable vinyl monomer.
  • the core ingredient component is prepared as a hydrophobic solution containing the antibiotic compound and the first polymerizable vinyl monomer.
  • the antibiotic compound is dissolved in the first polymerizable vinyl monomer (or miscible in the first polymerizable vinyl monomer) in the absence of a solvent.
  • an initiator is blended.
  • the initiator examples include oil-soluble radical polymerization initiators, and examples of the radical polymerization initiator include organic peroxides such as dilauroyl peroxide (10 hours half-life temperature T 1/2 : 61.6° C.), 1,1,3,3-tetramethylbutylperoxy-2-ethylhexanoate (10 hours half-life temperature T 1/2 : 65.3° C.), t-hexylperoxy-2-ethylhexanoate (10 hours half-life temperature T 1/2 : 69.4° C.), diisopropylperoxydicarbonate (10 hours half-life temperature T 1/2 : 40.5° C.), and benzoylperoxide (10 hours half-life temperature T 1/2 : 73.6° C.); and azo compounds such as 2,2′-azobisisobutyronitrile (10 hours half-life temperature T 1/2 : 60° C.), 2,2′-azobis(2,4-dimethylvaleronitrile)(10 hours half-life temperature T 1/2 : 51
  • the mixing ratio of the initiator relative to 100 parts by mass of the first polymerizable vinyl monomer is, for example, 0.01 parts by mass or more, preferably 0.1 parts by mass or more, more preferably 1 part by mass or more, particularly preferably 2.0 parts by mass or more, and usually, for example, 10 parts by mass or less.
  • the mixing ratio of the initiator is the above-described lower limit value or more, the conversion rate of the second polymerizable vinyl monomer in suspension polymerization to be described next can be increased.
  • the initiator is blended at the same time with the blending of the above-described antibiotic compound and the first polymerizable vinyl monomer, or before or after the blending.
  • the initiator is dissolved, when the antibiotic compound is dissolved in the first polymerizable vinyl monomer simultaneously.
  • Preparation of the hydrophobic solution may be performed, for example, at normal temperature, or as necessary, can be performed by heating to 30 to 100° C.
  • the hydrophobic solution is prepared at normal temperature without heating.
  • hydrophobic solution is suspended (aqueously dispersed) in water.
  • hydrophobic solution and water are blended, and the mixture is stirred homogeneously, thereby allowing the hydrophobic solution to be suspended.
  • a first water suspension liquid of the hydrophobic solution is obtained in this manner.
  • Conditions for the suspension are not particularly limited.
  • the suspension may be performed at normal temperature, or can be performed by heating to 30 to 100° C.
  • the suspension is performed without heating.
  • the mixing ratio of water relative to 100 parts by mass of the hydrophobic solution is, for example, 10 to 1000 parts by mass, preferably 50 to 500 parts by mass.
  • a dispersing agent is blended.
  • dispersing agents examples include water-soluble polymers such as polyvinyl alcohol (PVA, including partially saponified polyvinyl alcohol), polyvinyl pyrrolidone, gelatin, gum arabic, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cationized starch, polyacrylic acid and its sodium salt, and styrene maleic acid copolymer and its sodium salt; and inorganic dispersing agents such as tribasic calcium phosphate, colloidal silica, montmorillonite, magnesium carbonate, aluminum hydroxide, and zinc white.
  • PVA polyvinyl alcohol
  • PVA polyvinyl alcohol
  • polyvinyl pyrrolidone gelatin
  • gum arabic hydroxyethyl cellulose
  • hydroxypropyl cellulose carboxymethyl cellulose
  • cationized starch polyacrylic acid and its sodium salt
  • polyacrylic acid and its sodium salt and styrene maleic acid copolymer and its sodium
  • inorganic dispersing agent preferably, inorganic dispersing agent, and more preferably, tribasic calcium phosphate is used.
  • tribasic calcium phosphate when the tribasic calcium phosphate is used, and when the obtained controlled release particles are formulated into powder formulation (described later) or granular formulation (described later), re-dispersiveness of the powder formulation or granular formulation is improved, and occurrence of caking can be prevented.
  • the mixing ratio of the dispersing agent relative to 100 parts by mass of the hydrophobic solution is, for example, 0.1 to 20 parts by mass, preferably 0.1 to 15 parts by mass.
  • a surfactant can be used in combination along with the above-described dispersing agent.
  • the surfactant is blended to effectively prevent aggregation of the core in the suspension polymerization.
  • the surfactant include anionic surfactants such as sodium dodecylbenzenesulfonate (DBN), sodium lauryl sulfate, sodium di-2-ethylhexyl sulfosuccinate, sodium dodecyl diphenyl ether disulphonate, sodium nonyl diphenyl ether sulfonate, sodium polyoxyethylene alkyl ether sulfonate, ammonium polyoxyethylene alkyl ether phosphate, naphthalenesulfonic acid formaldehyde condensate sodium salt, and sodium dialkylsulfosuccinic acid; and non-ionic surfactants such as polyoxyethylene lauryl ether, polyoxyethylenenonylphenylether, polyoxyethylene monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene polyoxypropylene block copolymer,
  • the mixing ratio of the surfactant relative to 100 parts by mass of the hydrophobic solution is, for example, 0.0001 to 1.0 parts by mass, preferably 0.001 to 0.1 parts by mass.
  • dispersing agents and surfactants can be blended, for example, before or after the blending of the hydrophobic solution with water.
  • these dispersing agents and surfactants are blended in water before being blended with the hydrophobic solution.
  • An aqueous solution of the dispersing agent and the surfactant are prepared in this manner.
  • dispensers such as a homomixer, Disper, an ultrasonic homogenizer, a pressurized homogenizer, Milder, and a porous membrane injection disperser are used.
  • Homo Mixer is used, and its number of revolution is, for example, 200 to 20000 rpm, preferably 1500 to 15000 rpm.
  • the suspension time (stirring time) of the first suspension liquid is, for example, 20 minutes or less, preferably for 3 to 10 minutes.
  • the first polymerizable vinyl monomer is allowed to react (to be specific, vinyl polymerization) while stirring the first suspension liquid so as to maintain the suspension state of the first suspension liquid, thereby producing a polymer (first polymer) of the first polymerizable vinyl monomer. Furthermore, because the ingredient, the first polymerizable vinyl monomer, is in the hydrophobic phase (oil phase), it is called in situ polymerization.
  • the temperature of the first suspension liquid is increased so that the temperature of the first suspension liquid is higher than the 10 hours half-life temperature T 1/2 of the initiator by, for example, more than 0° C. to 30° C. or less, preferably, more than 5° C. to 20° C. or less.
  • the first suspension liquid can also be heated to the temperature of the 10 hours half-life temperature T 1/2 of the initiator.
  • the initiator undergoes thermal decomposition at a certain temperature, causing suspension polymerization to start.
  • the polymerization temperature in the first step is, for example, 30 to 100° C., preferably 40 to 80° C., more preferably 50 to 75° C.
  • the pressure at the time of suspension polymerization is not particularly limited, and suspension polymerization is carried out at normal pressure. Or, the suspension polymerization is carried out at high pressure. Preferably, the suspension polymerization is carried out at normal pressure.
  • the polymerization time in the first step is, for example, 1 hour or more, preferably 3 hours or more, more preferably 4 hours or more, and usually 10 hours or less.
  • the above-described suspension polymerization allows the antibiotic compound to be present in the matrix composed of the first polymer.
  • the core containing the first polymer and the antibiotic compound is formed.
  • the second polymerizable vinyl monomer is subjected to suspension polymerization.
  • the second polymerizable vinyl monomer to suspension polymerization, first, for example, the first suspension liquid after the reaction is cooled.
  • the suspension liquid after reaction is cooled, for example, by allowing the suspension liquid after reaction to stand to cool, or by water.
  • the cooling temperature of the first suspension liquid is a temperature which allows suppression of thermal decomposition of the initiator remaining in the core, to be specific, for example, 50° C. or less, preferably 40° C. or less, more preferably normal temperature or less, and usually 5° C. or more.
  • the first suspension liquid after reaction can also be used, for example, without cooling, in the next suspension polymerization of the second polymerizable vinyl monomer.
  • the second polymerizable vinyl monomer is blended with the first suspension liquid, and the mixture is allowed to react.
  • the second polymerizable vinyl monomer is prepared as an emulsified liquid containing the second polymerizable vinyl monomer.
  • the emulsified liquid is prepared by emulsifying the second polymerizable vinyl monomer in water in the presence of an emulsifier.
  • emulsifier examples include those surfactants described above, and preferably, anionic surfactants are used.
  • the mixing ratio of the emulsifier relative to 100 parts by mass of the emulsified liquid is, for example, 0.0001 to 1.0 parts by mass, preferably 0.001 to 0.1 parts by mass.
  • the emulsifier can be blended, for example, before or after the blending of the second polymerizable vinyl monomer with water.
  • the emulsifier is blended with water before blending with the second polymerizable vinyl monomer.
  • An aqueous solution of the emulsifier is prepared in this manner.
  • the mixing ratio of the second polymerizable vinyl monomer relative to 100 parts by mass of water is, for example, 10 to 1000 parts by mass, preferably 50 to 500 parts by mass.
  • the above-described disperser is used for emulsification of the second polymerizable vinyl monomer.
  • the above-described disperser is used.
  • Homo Mixer is used, and its number of revolution is higher than the number of revolution in the suspension of the first suspension liquid, to be specific, for example, 200 to 20000 rpm, preferably 1500 to 15000 rpm.
  • a silane coupling agent can be blended.
  • a silane coupling agent can be blended.
  • the silane coupling agent is, for example, an alkoxysilyl compound having at least a vinyl group or a (meth) acryloyl group, to be specific, for example, a vinyl group-containing alkoxysilyl compound such as vinyltrimethoxysilane and vinyltriethoxysilane; and (meth) acryloyl-group containing alkoxysilyl compounds such as methacryloxypropylmethyldimethoxysilane, 3-methacryloxypropyltrimethoxysilane, 3-methacryloxypropylmethyldiethoxysilane, 3-methacryloxypropyltriethoxysilane, and 3-acryloxypropyltrimethoxysilane.
  • a vinyl group-containing alkoxysilyl compound such as vinyltrimethoxysilane and vinyltriethoxysilane
  • (meth) acryloyl-group containing alkoxysilyl compounds such as methacryloxypropylmethyldimethoxysi
  • the mixing ratio of the silane coupling agent relative to 100 parts by mass of the second polymerizable vinyl monomer is, for example, 0.01 to 10 parts by mass, preferably 0.1 to 1 parts by mass.
  • the preparation of the emulsified liquid can be carried out, for example, at normal temperature, or as necessary, for example, while heating to 30 to 100° C.
  • the emulsified liquid is prepared at normal temperature without heating.
  • Emulsification time is, for example, 20 minutes or less, preferably for 3 to 20 minutes.
  • the prepared emulsified liquid is blended with the first suspension liquid, and the mixture is stirred to prepare a second suspension liquid.
  • the above-described disperser is used for the preparation of the above-described second suspension liquid.
  • Homo Mixer is used, and its number of revolution is, for example, 200 to 20000 rpm, preferably 1500 to 15000 rpm.
  • the suspension time (stirring time) of the second suspension liquid is, in view of sufficiently allowing the second polymerizable vinyl monomer to adsorb on the surface of the core, for example, 0.1 hour or more, preferably 1 hour or more, more preferably 2 hours or more, and usually 10 hours or less.
  • the second polymerizable vinyl monomer in the emulsified liquid is attached to (absorbed by) the core composed of the first polymer.
  • the temperature of the second suspension liquid is increased so that the temperature of the second suspension liquid is higher than the 10 hours half-life temperature T 1/2 of the initiator by, for example, more than 0° C. to 30° C. or less, preferably more than 5° C. to 20° C. or less.
  • the second suspension liquid can also be heated to the temperature of the 10 hours half-life temperature T 1/2 of the initiator.
  • the remaining initiator undergoes thermal decomposition at a certain temperature, causing suspension polymerization to start.
  • the polymerization temperature of the second step is the same as that of the polymerization temperature of the first step.
  • the pressure at the time of the suspension polymerization of the second suspension liquid is not particularly limited, and is a constant pressure.
  • the suspension polymerization can be carried out at high pressure.
  • the suspension polymerization is carried out at normal pressure.
  • the polymerization time of the second step is, for example, 0.1 hour or more, preferably 1 hour or more, more preferably 2 hours or more, and usually 10 hours or less.
  • the second polymerizable vinyl monomer is allowed to react while stirring the second suspension liquid so as to maintain the suspension state of the second suspension liquid, thereby producing a polymer (second polymer) of the second polymerizable vinyl monomer.
  • the suspension polymerization of the second polymerizable vinyl monomer allows covering of the core, and forming of the shell composed of the second polymer.
  • the second suspension liquid is cooled, for example, by allowing the second suspension liquid after reaction to stand to cool, or by water.
  • the cooling temperature is, for example, room temperature (20 to 30° C., to be more specific, 25° C.).
  • the antibiotic compound is present in the first polymer in the core.
  • the antibiotic compound when the antibiotic compound is solid at room temperature, in the matrix composed of the first polymer in the core, the miscible state is frozen, and the homogenous state is kept.
  • the antibiotic compound is miscible with (dissolved in) the first polymer in the core ( 2 ).
  • the suspension liquid including controlled release particles ( 1 ) including the core ( 2 ) and the shell ( 3 ) can be obtained.
  • the particle size of the controlled release particles is not particularly limited, and the average particle size (median size) is, for example, 1 ⁇ m to 1 mm, preferably 2 to 100 ⁇ m.
  • the core has a particle size, i.e., an average particle size (median size) of for example, 1 to 1000 ⁇ m, preferably 2 to 50 ⁇ m.
  • the shell has a thickness, i.e., the maximum thickness of, for example, 0.01 to 500 ⁇ m, preferably 0.05 to 50 ⁇ m.
  • the particle size of the core and the thickness of the shell are calculated from, for example, a TEM photograph of the obtained controlled release particles.
  • the particle size of the core can be also measured by taking out the particles composed only of the core from the suspension liquid after the first step, and measuring the particles composed only of the core by a laser diffraction scattering particle size distribution analyzer.
  • a suspension liquid in which controlled release particles are suspended can be obtained, the controlled release particles including the core containing the antibiotic compound, and the shell covering the core.
  • controlled release particles may be used as is (suspension liquid), that is, may be used as suspension formulation, or for example, may be formulated into a known form such as powder formulation or granular formulation, after solid-liquid separation by filtration and/or centrifugal separation, etc. and used.
  • suspension liquid can be dried by spraying or by air as is, to be formulated into forms such as powder formulation or granular formulation.
  • the suspension formulation has a solid content concentration (controlled release particles concentration) of, for example, 1 to 50 mass %, preferably 5 to 40 mass %.
  • the suspension formulation has an antibiotic compound concentration of, for example, 0.5 to 40 mass %, preferably 1 to 25 mass %.
  • powder formulation is excellent in flowability particularly when tribasic calcium phosphate is used as the dispersing agent.
  • water dispersion formulation or suspension formulation can be prepared again.
  • the powder formulation is excellent in re-dispersibility in water or forming re-suspension.
  • the transportation costs can be reduced, and furthermore, its application can be expanded.
  • the controlled release particles obtained by above-described production method includes a core in which the antibiotic compound is present in the first polymer obtained from the first polymerizable vinyl monomer; and a shell composed of the second polymer and formed to cover the core, and therefore by suppressing the releasing speed of the antibiotic compound, excellent controlled release properties can be achieved, and excellent lasting effects can be exhibited.
  • controlled release properties what is meant is that the encapsulated compound can be released gradually.
  • the emulsified liquid contains a silane coupling agent
  • a silanol group derived from the silane coupling agent is present in the shell, and the silanol group is capable of reacting with inorganic substance (to be specific, metal, metal oxide, etc.) or organic substance (to be specific, cellulose forming paper or lumber, etc.) that forms the base material.
  • inorganic substance to be specific, metal, metal oxide, etc.
  • organic substance to be specific, cellulose forming paper or lumber, etc.
  • the second polymerizable vinyl monomer has affinity with water that is higher than that of the first polymerizable vinyl monomer
  • affinity with water of the second polymerizable vinyl monomer may be substantially the same with that of the first polymerizable vinyl monomer
  • the second polymerizable vinyl monomer has affinity with water of substantially the same with affinity with water of the first polymerizable vinyl monomer.
  • such a second polymerizable vinyl monomer is hydrophobic.
  • Examples of such a second polymerizable vinyl monomer include (meth)acrylic acid alkyl ester, and preferably, (meth)acrylic acid alkyl ester having an alkyl moiety with 1 to 3 carbon atoms is used.
  • the (meth)acrylic acid alkyl ester having an alkyl moiety with 1 to 3 carbon atoms is used singly, as the first polymerizable vinyl monomer, for example, a combination of (meth)acrylic acid alkyl ester having 1 to 3 carbon atoms and (meth)acrylic acid monomer, preferably, a combination of (meth)acrylic acid alkyl ester (to be specific, methyl (meth)acrylate) having one carbon atom and methacrylic acid is selected.
  • the polar term ⁇ p,second polymer of the second polymer i.e., a polymer of such a second polymerizable vinyl monomer
  • ⁇ p,second polymer of the second polymer is, for example, 5.0 or more to below 6.5[(J/cm 3 ) 1/2 ], preferably 5.5 to 6.5[(J/cm 3 ) 1/2
  • the hydrogen bonding term ⁇ h,second polymer of the second polymer, the polymer of the second polymerizable vinyl monomer is, for example, 8.0[(J/cm 3 ) 1/2 ] or more and below 13.0[(J/cm 3 ) 1/2 ], preferably 9.0 to 11.0[(J/cm 3 ) 1/2 ].
  • the value of ⁇ p2 deducting the polar term ⁇ p,first polymer of the first polymer from the polar term ⁇ p,second polymer of the second polymer is, for example, ⁇ 0.5[(J/cm 3 ) 1/2 ] or more and below 2.0[(J/cm 3 ) 1/2 ], more preferably ⁇ 0.2 to 1.0[(J/cm 3 ) 1/2 ], even more preferably ⁇ 0.1 to 0.0[(J/cm 3 ) 1/2 ].
  • ⁇ h2 deducting the hydrogen bonding term ⁇ h,first polymer of the first polymer from the hydrogen bonding term ⁇ h,second polymer of the second polymer is, for example, ⁇ 2.0[(J/cm 3 ) 1/2 ] or more and below 2.0[(J/cm 3 ) 1/2 ], more preferably ⁇ 0.5 to 1.0[(J/cm 3 ) 1/2 ], and even more preferably ⁇ 0.3 to 0.0[(J/cm 3 ) 1/2 ].
  • affinity with water of the second polymer is defined as substantially the same as affinity with water of the first polymer.
  • hydrophobicity of the second polymerizable vinyl monomer is substantially the same as hydrophobicity of the first polymerizable vinyl monomer.
  • the antibiotic compound that is not miscible with the shell is preferably used. That is, for the second polymer forming the shell, preferably, the second polymer that is not miscible with the antibiotic compound is used.
  • the shell ( 3 ) is composed of a polymer (second polymer) of a second polymerizable vinyl monomer having higher affinity with water than that of the first polymerizable vinyl monomer.
  • the shell ( 3 ) functions as a barrier layer which prevents the antibiotic compound present in the core ( 2 ) from leaking out of the controlled release particles ( 1 ).
  • controlled release properties of the controlled release particles ( 1 ) are improved, and more excellent lasting effects can be exhibited.
  • OIT trade name “KATHON 893T” (“KATHON” is registered trademark), 2-n-octyl-4-isothiazoline-3-one, molecular weight 213, melting point: below 20° C., water solubility: 300 ppm, polar term ⁇ p,compound of solubility parameter ⁇ : 5.47[(J/cm 3 ) 1/2 ], hydrogen bonding term ⁇ h,compound of solubility parameter ⁇ : 5.87[(J/cm 3 ) 1/2 ], manufactured by Rohm and Haas Company IPBC: trade name “Fungitrol 400”, 3-iodo-2-propynylbutylcarbamate, molecular weight 281, melting point: 60° C., water solubility: 150 ppm, polar term ⁇ p,compound of solubility parameter ⁇ : 3.23[(J/cm 3 ) 1/2 ], hydrogen bonding term ⁇ h,compound of solubility parameter ⁇ : 7.83 [(J/cm 3
  • Propiconazole 1-[2-(2,4-dichlorophenyl)-4-n-propyl-1,3-dioxolane-2-ylmethyl]-1H-1,2,4-triazole, molecular weight 342, melting point: below 20° C., water solubility: 110 ppm, polar term ⁇ p,compound of solubility parameter ⁇ : 6.55[(J/cm 3 ) 1/2 ], hydrogen bonding term ⁇ h,compound of solubility parameter ⁇ : 9.44[(J/cm 3 ) 1/2 ], manufactured by HAKKO TSUSHO CO., LTD.
  • Flusilazole bis(4-fluorophenyl) methyl (1H-1,2,4-triazole-1-ylmethylsliane), molecular weight 315, melting point: 54° C., water solubility: 45 ppm, polar term ⁇ p,compound of solubility parameter ⁇ : 5.95[(J/cm 3 ) 1/2 ], hydrogen bonding term ⁇ h,compound of solubility parameter ⁇ : 6.85[(J/cm 3 ) 1/2 ], manufactured by ARBROWN CO., LTD.
  • Methacrylic acid water solubility: 8.9 mass %, polar term ⁇ p,monomer unit of solubility parameter ⁇ as monomer unit: 7.13[(J/cm 3 ) 1/2 ], hydrogen bonding term ⁇ h,monomer unit of solubility parameter ⁇ as monomer unit: 13.03 [(J/cm 3 ) 1/2 ], manufactured by Mitsubishi Rayon Co., Ltd.
  • Ethylene glycol dimethacrylate trade name “Light Ester EG”, water solubility: 5.37 ppm, polar term ⁇ p,monomer unit of solubility parameter ⁇ as monomer unit: 5.37[(J/cm 3 ) 1/2 ], hydrogen bonding term ⁇ h,monomer unit of solubility parameter ⁇ as monomer unit: 10.42[(J/cm 3 ) 1/2 ], manufactured by Kyoeisha Chemical Co., Ltd.
  • Dilauroyl peroxide trade name “PEROYL® L” (“PEROYL” is registered trademark), manufactured by NOF CORPORATION TCP-10U: trade name, a suspension liquid of 10% tribasic calcium phosphate [Ca 3 (PO 4 ) 2 ].
  • Ca(OH) 2 manufactured by Matsuo Yakuhin Sangyo K. K.
  • PLYSURF A210G trade name, “PLYSURF” is registered trademark, polyoxyethylene phosphate, non-ionic surfactant, manufactured by DAI-ICHI KOGYO SEIYAKU CO., LTD.
  • 2-hydroxyethyl methacrylate hydrophilic (miscible with water), polar term ⁇ p,monomer unit of solubility parameter ⁇ as monomer unit: 7.48[(J/cm 3 ) 1/2 ], hydrogen bonding term ⁇ h,monomer unit of solubility parameter ⁇ as monomer unit: 16.98[(J/cm 3 ) 1/2 ], manufactured by Nippon Shokubai Co., Ltd.
  • Pelex OT-P trade name, “Pelex” is registered trademark, sodium dialkyl sulfosuccinic acid, manufactured by Kao Corporation
  • A200 mL beaker (1) was charged with 60.0 g of OIT, 30.0 g of methyl methacrylate, 5.0 g of methacrylic acid, 5.0 g of ethylene glycol dimethacrylate, and 1.9 g of dilauroyl peroxide, and then the mixture was stirred at room temperature, thereby preparing a homogeneous hydrophobic solution.
  • a 1000 mL beaker (2) was charged with 120.0 g of ion-exchange water, 120.0 g of TCP-10U, and 1.0 g of a solution of 5% PLYSURF A210G in water, and then the mixture was stirred at room temperature, thereby producing a homogeneous suspension liquid.
  • the hydrophobic solution was added to the 1000 mL beaker (2), and the mixture was stirred with T.K. Homo Mixer MARK Model 2.5 (manufactured by PRIMIX Corporation) at a number of revolution of 5000 rpm for 5 min, thereby suspending the hydrophobic solution, and preparing a suspension liquid.
  • suspension liquid was transferred to a 500 mL, 4-neck flask equipped with a stirrer, a reflux condenser, a thermometer, and a nitrogen inlet tube, and subjected to suspension polymerization under nitrogen gas current, while stirring and increasing the temperature (first step).
  • the suspension polymerization was started when the temperature of the suspension liquid reached 65° C. while the temperature of the suspension liquid was increasing, and then subsequently, the temperature of the suspension liquid was kept at 70° C. for 2 hours.
  • a 200 mL beaker (3) was charged with 17.2 g of ion-exchange water and 22.8 g of a solution of 1% Pelex OT-P in water, and then the mixture was stirred at room temperature, thereby preparing a homogenous aqueous solution.
  • the emulsified liquid was added to the suspension liquid while stirring the suspension liquid cooled to room temperature after the reaction, and the mixture was stirred for 2 hours.
  • the suspension polymerization was started when the temperature of the suspension liquid reached 65° C. while the temperature of the suspension liquid was increasing, and then subsequently, the temperature of the suspension liquid was kept at 70° C. for 3 hours.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing OIT and a shell covering the core was obtained in this manner.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing OIT and a shell covering the core was obtained in the same manner as in Example 1, except that 30.0 g of methyl methacrylate in the hydrophobic solution was changed to 30.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing OIT and a shell covering the core was obtained in the same manner as in Example 1, except that 30.0 g of methyl methacrylate in the hydrophobic solution was changed to 30.0 g of isobutyl methacrylate, and the 200 mL beaker (3) was charged with 20.0 g of methyl methacrylate and 20.0 g of 2-hydroxyethyl methacrylate instead of 40.0 g of methyl methacrylate to be emulsified.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing OIT and a shell covering the core was obtained in the same manner as in Example 1, except that 30.0 g of methyl methacrylate in the hydrophobic solution was changed to 30.0 g of isobutyl methacrylate, and the 200 mL beaker (3) was charged with 40.0 g of 2-hydroxyethyl methacrylate instead of 40.0 g of methyl methacrylate to be emulsified.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing IPBC and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of IPBC, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing IPBC and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of IPBC, 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate, and the 200 mL beaker (3) was charged with 40.0 g of 2-hydroxyethyl methacrylate instead of 40.0 g of methyl methacrylate to be emulsified.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing Propiconazole and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of Propiconazole, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing Propiconazole and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of Propiconazole, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate, and the 200 mL beaker (3) was charged with 40.0 g of 2-hydroxyethyl methacrylate instead of 40.0 g of methyl methacrylate to be emulsified.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing Flusilazole and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of Flusilazole, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing Flusilazole and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of Flusilazole, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate, and the 200 mL beaker (3) was charged with 40.0 g of 2-hydroxyethyl methacrylate instead of 40.0 g of methyl methacrylate to be emulsified.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing prochloraz and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of prochloraz, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing prochloraz and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of prochloraz, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate, and the 200 mL beaker (3) was charged with 40.0 g of 2-hydroxyethyl methacrylate instead of 40.0 g of methyl methacrylate to be emulsified.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing cyfluthrin and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of cyfluthrin, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles including a core containing cyfluthrin and a shell covering the core was produced in the same manner as in Example 1, except that 60.0 g of Off in the hydrophobic solution was changed to 25.0 g of prochloraz, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate, and the 200 mL beaker (3) was charged with 40.0 g of 2-hydroxyethyl methacrylate instead of 40.0 g of methyl methacrylate to be emulsified.
  • a 200 mL beaker (1) was charged with 60.0 g of OIT, 30.0 g of methyl methacrylate, 5 g of methacrylic acid, 5.0 g of ethylene glycol dimethacrylate, and 1.9 g of dilauroyl peroxide, and then the mixture was stirred at room temperature, thereby preparing a homogenous hydrophobic solution.
  • a 1000 mL beaker (2) was charged with 120.0 g of ion-exchange water, 120.0 g of TCP-10U, and 1.0 g of a solution of 5% PLYSURF A210G in water, and then the mixture was stirred at room temperature, thereby producing a homogenous suspension liquid.
  • the hydrophobic solution was added to the 1000 mL beaker (2), and the mixture was stirred with T.K. Homo Mixer MARK Model 2.5 (manufactured by PRIMIX Corporation) at a number of revolution of 5000 rpm for 5 min, thereby dispersing the hydrophobic solution, and preparing a suspension liquid.
  • suspension liquid was transferred to a 500 mL, 4-neck flask equipped with a stirrer, a reflux condenser, a thermometer, and a nitrogen inlet tube, and subjected to suspension polymerization under nitrogen gas current, while stirring and increasing the temperature (first step).
  • the suspension polymerization was started when the temperature of the suspension liquid reached 65° C. while the temperature of the suspension liquid was increasing, and then subsequently, the temperature of the suspension liquid was kept at 70° C. for 2 hours.
  • a suspension liquid (suspension formulation) of controlled release particles containing OIT was obtained in this manner.
  • a suspension liquid (suspension formulation) of controlled release particles containing OIT was produced in the same manner as in Comparative Example 1, except that 30.0 g of methyl methacrylate in the hydrophobic solution was changed to 30.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles containing IPBC was produced in the same manner as in Comparative Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of IPBC, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles containing Propiconazole was produced in the same manner as in Comparative Example 1, except that 60.0 g or OIT in the hydrophobic solution was changed to 25.0 g of Propiconazole, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles containing Flusilazole was produced in the same manner as in Comparative Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of Flusilazole, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles containing prochloraz was produced in the same manner as in Comparative Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of prochloraz, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • a suspension liquid (suspension formulation) of controlled release particles containing cyfluthrin was produced in the same manner as in Comparative Example 1, except that 60.0 g of OIT in the hydrophobic solution was changed to 25.0 g of cyfluthrin, and 30.0 g of methyl methacrylate was changed to 65.0 g of isobutyl methacrylate.
  • Example 1 Example 2
  • Example 3 Example 4
  • Example 5 Example 6
  • Example 7 Hydrophobic Solution Core Ingredient Component Antibiotic Compound OIT 60.0 60.0 60.0 60.0 — — — IPBC — — — — 25.0 25.0 — Propiconazole — — — — — 25.0 Flusilazole — — — — — — — — Prochloraz — — — — — — — — Cyfluthrin — — — — — — — — — First Miscible Monomer Methyl Methacrylate 30.0 — — — — — — — — — Polymerizable Isobutyl Methacrylate — 30.0 30.0 30.0 65.0 65.0 65.0 65.0 Vinyl Methacrylic Acid 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Monomer Crosslinkable Ethylene Glycol 5.0 5.0 5.0
  • Table 2 to Table 4 show the results of calculation along with the polar term ⁇ p,compound and the hydrogen bonding term ⁇ h,compound of the solubility parameter ⁇ of the antibiotic compound (ref: Table 1).
  • Example 4 The suspension liquid (suspension) of Example 4 was freeze-dried, then dispersed in a bisphenol liquid epoxy resin, and thereafter cured with amine. Then, the cured product was cut with an ultramicrotome to expose its cross section; the cross section was dyed with osmium tetroxide, and as necessary, also with ruthenium tetroxide; the cross section was cut out with an ultramicrotome into extremely thin slices, thereby preparing samples. The prepared samples were observed with a transmission electron microscope (model number “H-7100”, manufactured by Hitachi, Ltd.).
  • FIG. 1 shows an image-processed TEM photograph of Example 4.
  • Controlled release properties test was conducted for the OIT-containing controlled release particles of Examples 1 to 4 and Comparative Example 2 in the following manner.
  • suspension liquids (suspension formulation) of controlled release particles obtained in Examples 1 to 4 and Comparative Example 2 were added to a commercially available acrylic styrene emulsion while stirring so that the OIT concentration was 0.15 mass %, and the mixture was stiffed for 1 hour.
  • the coating was dried at 40° C. for 24 hours, thereby producing a controlled release particles-containing film, and thereafter, the controlled release particles-containing film was cut into a size of 7 cm ⁇ 15 cm, thereby producing test pieces.
  • the test pieces were attached to Dewpanel Weather Meter, and exposed to continuous rainfall for 2 weeks.
  • test pieces were cut into a size of 2.5 cm ⁇ 2.5 cm, 10 mL of methanol was added thereto, and OIT was extracted using an ultrasonic washer for 30 minutes.
  • the OTT amount extracted as described above was measured using HPLC, and the remaining rate of OIT of controlled release particles in controlled release particles-containing film was calculated from the unexposed test pieces and exposed test pieces.
  • the controlled release properties test was conducted for the controlled release particles in the following manner.
  • a suspension liquid of controlled release particles was prepared such that the antibiotic compound content of the controlled release particles of each of Examples 5 to 12 and Comparative Examples 3 to 6 was 100 mg.
  • the prepared suspension liquids were slowly poured individually onto the filter papers, and thereafter dried in air.
  • Controlled release properties test was conducted for cyfluthrin-containing controlled release particles of Examples 13, 14, and Comparative Example 7 in the following manner.
  • the prepared suspension liquids were poured slowly, and thereafter dried in air.
  • the controlled-release rate of the cyfluthrin was calculated using GC based on the ion-exchange water/methanol mixture liquid collected for the third time. The results are shown in Tables 3 and 4.
  • Controlled release particles of the present invention can be applied (or blended) to various industrial products, for example, can be blended in indoor/outdoor paint, rubber, fiber, resin, plastic, adhesive, joint mixture, sealing agent, building material, caulking agent, soil treating agent, lumber, white water in paper-making processes, pigment, treatment liquid for printing plates, cooling water, ink, cutting oil, cosmetic products, nonwoven fabric, spinning oil, leather; and allows controlled-release of the antibiotic compound that is contained to exhibit lasting effects of the antibiotic compound.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
US14/003,271 2011-03-11 2012-03-08 Controlled release particles Expired - Fee Related US9511030B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011054628 2011-03-11
JP2011-054628 2011-03-11
JP2012-037885 2012-02-23
JP2012037885A JP6083936B2 (ja) 2011-03-11 2012-02-23 徐放性粒子の製造方法
PCT/JP2012/055968 WO2012124598A1 (ja) 2011-03-11 2012-03-08 徐放性粒子

Publications (2)

Publication Number Publication Date
US20130337073A1 US20130337073A1 (en) 2013-12-19
US9511030B2 true US9511030B2 (en) 2016-12-06

Family

ID=46830671

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/003,271 Expired - Fee Related US9511030B2 (en) 2011-03-11 2012-03-08 Controlled release particles

Country Status (4)

Country Link
US (1) US9511030B2 (enExample)
JP (1) JP6083936B2 (enExample)
CN (1) CN103415207A (enExample)
WO (1) WO2012124598A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111424B2 (en) 2013-05-17 2018-10-30 3M Innovative Properties Company Release of biologically active agents from polymeric composite particles

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6109502B2 (ja) * 2012-07-13 2017-04-05 大阪ガスケミカル株式会社 抗生物活性粒子およびその製造方法
US9987233B2 (en) 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
WO2015030213A1 (ja) * 2013-08-30 2015-03-05 日本エンバイロケミカルズ株式会社 徐放性粒子、その製造方法、成形材料および成形品
CN105085778B (zh) * 2014-04-22 2018-11-16 广东华润涂料有限公司 用于缓释功能成分的涂料组合物用水性胶乳、其制备方法以及应用
MX2017003638A (es) * 2014-09-19 2017-11-08 Eupraxia Pharmaceuticals Inc Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
MX2018005035A (es) 2015-10-27 2018-09-06 Eupraxia Pharmaceuticals Inc Formulaciones de liberacion sostenida de anestesicos locales.
JP6830666B2 (ja) * 2017-09-22 2021-02-17 新中村化学工業株式会社 コアシェル型農薬粒剤組成物及びその製造方法
US10881103B2 (en) * 2017-11-06 2021-01-05 National Chung Shan Institute Of Science And Technology Biocide-encapsulated microcapsule for use in paint
EP4212577A4 (en) 2020-09-11 2024-09-18 Osaka Gas Chemicals Co., Ltd. ADDITIVE FOR RESIN MIXING
EP4304878A4 (en) * 2021-03-08 2025-01-29 Regents of the University of Michigan Crosslinked ion-exchange materials, related methods, and related articles

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59145265A (ja) 1983-02-04 1984-08-20 Sumitomo Naugatuck Co Ltd 接着剤組成物
JPS60132642A (ja) 1983-11-25 1985-07-15 アライド　コロイズ　リミテツド 重合体ビーズの製造方法
JPS6186941A (ja) 1984-10-03 1986-05-02 Japan Synthetic Rubber Co Ltd 含油マイクロカプセルの製造方法
JPS61236702A (ja) 1985-04-10 1986-10-22 Nippon Paint Co Ltd 抗有害生物性を有する微小樹脂粒子
US4656205A (en) 1983-11-25 1987-04-07 Allied Colloids Ltd. Manufacture of polymeric beads
CA2082892A1 (en) 1991-11-15 1993-05-16 Ekkehard Jahns Microcapsules with solid core
US5225279A (en) * 1985-04-30 1993-07-06 Rohm And Haas Company Solvent core encapsulant composition
JPH0753835A (ja) 1993-08-10 1995-02-28 Takeda Chem Ind Ltd 有効成分を含有するコアポリマー、コアシェルポリマーおよびそれらの製造法
JPH10324601A (ja) 1997-04-11 1998-12-08 Rohm & Haas Co 生物活性物質の投与方法
CA2321440A1 (en) 1998-02-20 1999-08-26 Bayer Aktiengesellschaft Pearl polymerizate formulations
JP2001502733A (ja) 1996-10-24 2001-02-27 バイエル・アクチエンゲゼルシヤフト 汚止めペイント
WO2001037660A1 (fr) 1999-11-19 2001-05-31 Nof Corporation Preparation du type dispersion aqueuse a liberation prolongee, et procede de production correspondant
JP2001247409A (ja) 1999-12-27 2001-09-11 Takeda Chem Ind Ltd 微生物増殖抑制剤含有マイクロカプセルおよび微生物増殖抑制剤含有マイクロカプセルの製造方法
JP2002513038A (ja) 1998-05-01 2002-05-08 ミネソタ マイニング アンド マニュファクチャリング カンパニー 農業用途で有用な生物活性な薬剤の配送手段としての微小球
JP2002513039A (ja) 1998-05-01 2002-05-08 スリーエム イノベイティブ プロパティズ カンパニー 抗微生物剤送達系
JP2004331625A (ja) 2003-05-12 2004-11-25 Nof Corp 水分散型のフェロモン徐放製剤およびその製造方法
US20050282011A1 (en) 2004-06-21 2005-12-22 Nissin Chemical Industry Co., Ltd. Microcapsule emulsion and method for producing the same
JP2006035210A (ja) 2004-06-21 2006-02-09 Nisshin Chem Ind Co Ltd マイクロカプセルエマルジョン及びその製造方法
US20070215000A1 (en) 2006-03-16 2007-09-20 Reybuck Sarah E Blends of encapsulated biocides
JP2008074809A (ja) 2006-09-25 2008-04-03 Sumitomo Chemical Co Ltd 被覆粉状農薬
JP2008218154A (ja) 2007-03-02 2008-09-18 Citizen Electronics Co Ltd 光源装置及び光源装置を備えた表示装置
JP2008239562A (ja) 2007-03-28 2008-10-09 Sumitomo Chemical Co Ltd 常温で固体の生理活性物質のマイクロカプセル組成物の製造方法
JP2008239561A (ja) 2007-03-28 2008-10-09 Sumitomo Chemical Co Ltd 常温で固体の生理活性物質のマイクロカプセル組成物の製造方法
US20120172334A1 (en) * 2009-09-11 2012-07-05 Japan Envirochemicals, Ltd. Controlled release particles and method for producing the same
US20130337072A1 (en) * 2011-03-11 2013-12-19 Japan Envirochemicals, Ltd. Controlled release particles and production method thereof
US20150010635A1 (en) * 2011-12-28 2015-01-08 Japan Envirochemicals, Ltd. Controlled release particles, wood treatment agent, and producing method thereof
US20150141549A1 (en) * 2012-07-13 2015-05-21 Japan Envirochemicals, Ltd. Antibiotic particles and production method thereof

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59145265A (ja) 1983-02-04 1984-08-20 Sumitomo Naugatuck Co Ltd 接着剤組成物
JPS60132642A (ja) 1983-11-25 1985-07-15 アライド　コロイズ　リミテツド 重合体ビーズの製造方法
US4656205A (en) 1983-11-25 1987-04-07 Allied Colloids Ltd. Manufacture of polymeric beads
US5073276A (en) 1983-11-25 1991-12-17 Exxon Research And Engineering Co. Polymer article of manufacture
JPS6186941A (ja) 1984-10-03 1986-05-02 Japan Synthetic Rubber Co Ltd 含油マイクロカプセルの製造方法
JPS61236702A (ja) 1985-04-10 1986-10-22 Nippon Paint Co Ltd 抗有害生物性を有する微小樹脂粒子
US4923894A (en) 1985-04-10 1990-05-08 Nippon Paint Co., Ltd. Polymeric microparticles having pesticidal activity
US5225279A (en) * 1985-04-30 1993-07-06 Rohm And Haas Company Solvent core encapsulant composition
CA2082892A1 (en) 1991-11-15 1993-05-16 Ekkehard Jahns Microcapsules with solid core
JPH05212271A (ja) 1991-11-15 1993-08-24 Basf Ag 固体芯物質を有するマイクロカプセル
JPH0753835A (ja) 1993-08-10 1995-02-28 Takeda Chem Ind Ltd 有効成分を含有するコアポリマー、コアシェルポリマーおよびそれらの製造法
US6365066B1 (en) 1996-10-24 2002-04-02 Bayer Aktiengesellschaft Antifouling paint
JP2001502733A (ja) 1996-10-24 2001-02-27 バイエル・アクチエンゲゼルシヤフト 汚止めペイント
US5972363A (en) 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition
JPH10324601A (ja) 1997-04-11 1998-12-08 Rohm & Haas Co 生物活性物質の投与方法
CA2321440A1 (en) 1998-02-20 1999-08-26 Bayer Aktiengesellschaft Pearl polymerizate formulations
JP2002503679A (ja) 1998-02-20 2002-02-05 バイエル・アクチエンゲゼルシヤフト パール重合体調合物
US6471975B1 (en) 1998-05-01 2002-10-29 3M Innovative Properties Company Microspheres as a delivery vehicle for bio-active agents useful in agricultural applications
US7354596B1 (en) 1998-05-01 2008-04-08 3M Innovative Properties Company Anti-microbial agent delivery system
JP2002513038A (ja) 1998-05-01 2002-05-08 ミネソタ マイニング アンド マニュファクチャリング カンパニー 農業用途で有用な生物活性な薬剤の配送手段としての微小球
JP2002513039A (ja) 1998-05-01 2002-05-08 スリーエム イノベイティブ プロパティズ カンパニー 抗微生物剤送達系
WO2001037660A1 (fr) 1999-11-19 2001-05-31 Nof Corporation Preparation du type dispersion aqueuse a liberation prolongee, et procede de production correspondant
EP1230855A1 (en) 1999-11-19 2002-08-14 Nof Corporation Sustained-release preparation of aqueous dispersion type and process for producing the same
JP2001247409A (ja) 1999-12-27 2001-09-11 Takeda Chem Ind Ltd 微生物増殖抑制剤含有マイクロカプセルおよび微生物増殖抑制剤含有マイクロカプセルの製造方法
JP2004331625A (ja) 2003-05-12 2004-11-25 Nof Corp 水分散型のフェロモン徐放製剤およびその製造方法
US20050282011A1 (en) 2004-06-21 2005-12-22 Nissin Chemical Industry Co., Ltd. Microcapsule emulsion and method for producing the same
JP2006035210A (ja) 2004-06-21 2006-02-09 Nisshin Chem Ind Co Ltd マイクロカプセルエマルジョン及びその製造方法
US20070215000A1 (en) 2006-03-16 2007-09-20 Reybuck Sarah E Blends of encapsulated biocides
JP2007246527A (ja) 2006-03-16 2007-09-27 Rohm & Haas Co カプセル化殺生物剤のブレンド
JP2008074809A (ja) 2006-09-25 2008-04-03 Sumitomo Chemical Co Ltd 被覆粉状農薬
JP2008218154A (ja) 2007-03-02 2008-09-18 Citizen Electronics Co Ltd 光源装置及び光源装置を備えた表示装置
JP2008239562A (ja) 2007-03-28 2008-10-09 Sumitomo Chemical Co Ltd 常温で固体の生理活性物質のマイクロカプセル組成物の製造方法
JP2008239561A (ja) 2007-03-28 2008-10-09 Sumitomo Chemical Co Ltd 常温で固体の生理活性物質のマイクロカプセル組成物の製造方法
US20120172334A1 (en) * 2009-09-11 2012-07-05 Japan Envirochemicals, Ltd. Controlled release particles and method for producing the same
US20130337072A1 (en) * 2011-03-11 2013-12-19 Japan Envirochemicals, Ltd. Controlled release particles and production method thereof
US20150010635A1 (en) * 2011-12-28 2015-01-08 Japan Envirochemicals, Ltd. Controlled release particles, wood treatment agent, and producing method thereof
US20150141549A1 (en) * 2012-07-13 2015-05-21 Japan Envirochemicals, Ltd. Antibiotic particles and production method thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Arun, A., et al., "In Vitro Drug Release Studies of 2-Hydroxyethyl Acrylate or 2-Hydroxypropyl Methacrylate-4-[1E,4E)-5[4-Acryloyloxy)Phenyl]-3OXOPENTA-1,4-Dienyl} Phenyl Acrylate Copolymer Beads," Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2005, vol. 73B, No. 2, pp. 291-300.
Croswell, Roger W. et al., "Suspension Polymerization for Preparation of Timed-Release Dosage Forms," Journal of Pharmaceutical Sciences, 1974, vol. 63, No. 3, pp. 440-442.
Iconomopoulou, S.M., et al., "Incorporation of Low Molecular Weight Biocides Into Polystyrene-Divinyl Benzene Beads With Controlled Release Characteristics," Journal of Controlled Release, 2005, vol. 102, No. 1, pp. 223-233.
International Search Report (PCT/ISA/210) mailed on Jun. 12, 2012, by the Japanese Patent Office as the International Searching Authority for International Application No. PCT/JP2012/055968.
Kassem, Aly A., "Formulation and Evaluation of Controlled Dissolution Phenobarbitone Macremolecular Products Employing In-Situ Suspension Polymerization With Methylmethacrylate," Egyptian Journal of Pharmaceutical Sciences, 1978, vol. 19, No. 1-4, pp. 143-162.
Kosmetik, et al. "Perlpolymerisate, Eine Neue Perorale Darreichungsform Und Ihre Beeinflussung Durch Arzneistoffe," Praparative Pharmazie, 1970, vol. 6, No. 9/10, pp. 149-154.
Masayoshi, Okubo, et al., "Production of Composite Polymer Particles Encapsulating Hinokitiol," Japan Chemical Society Lecture Preliminary Drafts, 2001, vol. 79, No. 1, p. 425.
Notice of Reasons for Refusal issued on Feb. 21, 2014, by the Japanese Patent Office in Japanese Patent Application No. 2010-201604, and an partial English translation of the Notice. (7 pages).
Notification Concerning Transmittal of International Preliminary Report on Patentability (Form PCT/ISA/326), Notification of Transmittal of Translation of the International Preliminary Report on Patentability (Forms of PCT/IB/373 and PCT/IB/338) and the Written Opinion of the International Searching Authority (Form PCT/ISA/237) issued on Aug. 6, 2012 in the corresponding International Application No. PCT/JP2012/055968. (14 Pages).
Vyas, S.P., et al.,"Formulation of Sustained Release Nitrofurantoin by Interfacial Copolymerization Method," Indian Drugs, 1980, vol. 18, No. 1 pp. 8-10.
Written Opinion (PCT/ISA/237) mailed on Jun. 12, 2012, by the Japanese Patent Office as the International Searching Authority for International Application No. PCT/JP2012/055968.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111424B2 (en) 2013-05-17 2018-10-30 3M Innovative Properties Company Release of biologically active agents from polymeric composite particles

Also Published As

Publication number Publication date
WO2012124598A1 (ja) 2012-09-20
US20130337073A1 (en) 2013-12-19
JP6083936B2 (ja) 2017-02-22
CN103415207A (zh) 2013-11-27
JP2012207012A (ja) 2012-10-25

Similar Documents

Publication Publication Date Title
US9511030B2 (en) Controlled release particles
US8808752B2 (en) Controlled release particles and method for producing the same
US9138417B2 (en) Controlled release particles and production method thereof
US20150141549A1 (en) Antibiotic particles and production method thereof
AU2013289339B2 (en) Insecticidal formulations of microcapsules
EP2405743A1 (de) Zusammensetzung umfassend pestizid und benzotriazol uv-absorber
JP2010531319A5 (enExample)
TR201816012T4 (tr) Mi̇krokapsüllenmi̇ş etken maddeleri̇n salim hizini modüle etmeye yöneli̇k bi̇r yöntem
CN116369315A (zh) 苯甲酰脲与拟除虫菊酯的稳定共制剂
JP5873790B2 (ja) 徐放性粒子およびその製造方法
JP5646512B2 (ja) 粘度が増加した油性の農薬組成物
JP2012207012A5 (enExample)
BR112016019257B1 (pt) Composição de grânulos dispersíveis em água
US20150010635A1 (en) Controlled release particles, wood treatment agent, and producing method thereof
JP6646950B2 (ja) 木材保存剤および木材保護塗料
WO2013100102A1 (ja) 徐放性粒子、木材処理剤およびその製造方法
TW201632063A (zh) 持續釋放性粒子及其製造方法
WO2003077651A1 (en) Microparticle formulation with reduced aquatic toxicity
JPH02275803A (ja) 改良された有害生物防除製剤
BR112020025690B1 (pt) Coformulação com lambda-cialotrina e novaluron, processo de preparação e método de controle ou prevenção contra pragas indesejadas

Legal Events

Date Code Title Description
AS Assignment

Owner name: JAPAN ENVIROCHEMICALS, LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OSHIMA, JUNJI;SUGIYAMA, TAKAYUKI;REEL/FRAME:031141/0358

Effective date: 20130807

AS Assignment

Owner name: OSAKA GAS CHEMICALS CO., LTD., JAPAN

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:JAPAN ENVIROCHEMICALS, LTD.;OSAKA GAS CHEMICALS CO., LTD.;REEL/FRAME:035962/0485

Effective date: 20150401

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20241206